PackGene Biotech Lands The Newest Round Of Financing From Kaitai Capital

In recent days, PackGene Biotech just received the newest round of financing from Kaitai Capital, the total amount is unknown. PackGene Biotech is dedicated to solving the clinical production bottleneck of viral vectors in the gene therapy industry and improving the efficiency and effectiveness of viral carrier drug production through its technology platform.

PackGene Biotech is a gene-drug platform developed for the production and delivery of gene therapy drugs. The company has offices in Guangzhou and Massachusetts. The company's team members have extensive experience in gene therapy viral vector design, gene therapy drug clinical management and production, and have participated in the clinical development, production and testing of various gene therapy drugs at home and abroad.

The investor believes that the breakthrough in technology will greatly reduce the cost of gene therapy drugs and benefit the majority of patients, and PackGene Biotech is the right company for this goal.

Kaitai Capital was founded in 2009, it is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business.